Egalet Ltd. is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Using our proprietary technology platform, we have developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical tampering while also providing tailored release of the active pharmaceutical ingredient, or API. Our lead product candidates, Egalet-001 and Egalet-002, are abuse-deterrent, extended-release, oral formulations of commonly prescribed opioids in development for the treatment of moderate to severe pain. Our technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles. In addition to our two clinical-stage product candidates, we are developing a portfolio of preclinical, abuse-deterrent product candidates for the treatment of pain and other conditions. We exclusively own the rights to Egalet-001 and Egalet-002 and our platform technology.